TIDMRENE

RNS Number : 9323D

ReNeuron Group plc

08 March 2022

ReNeuron Group plc

("ReNeuron" or the "Company")

Block Listing Review

and Total Voting Rights

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements.

 
 Name:                               ReNeuron Group plc 
 Name of Scheme:                     ReNeuron Share Option Schemes 
                                    ------------------------------------------ 
 Period of Return:                   From 1 September 2021 to 28 February 2022 
                                    ------------------------------------------ 
 Balance of unallotted securities    582,990 Ordinary Shares (of 1p each) 
  under scheme(s) from previous 
  return: 
                                    ------------------------------------------ 
 Plus : The amount by which 
  the block scheme(s) has been 
  increased since the date 
  of the last Review (if any 
  increase has been applied 
  for):                              3,000,000 
                                    ------------------------------------------ 
 Less : Number of securities 
  issued/allotted under scheme(s) 
  during period                      127,221 
                                    ------------------------------------------ 
 Equals : Balance under scheme(s)    3,455,769 Ordinary Shares 
  not yet issued/allotted at 
  end of period: 
                                    ------------------------------------------ 
 Number and class of securities      20,000 ordinary shares on 13 May 2010 
  originally admitted and the 
  date of admission: 
                                    ------------------------------------------

Total Voting Rights

At 28 February 2022, the Company had 57,063,623 Ordinary Shares in issue, each carrying one voting right.

As the Company holds no ordinary shares in treasury, the figure of 57,063,323 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

ENDS

Contacts:

 
 ReNeuron                                                        www.reneuron.com/investors 
 Iain Ross, Chairman                                                        Via Walbrook PR 
 Catherine Isted, Chief Financial Officer 
 
 Stifel Nicolaus Europe Limited (NOMAD 
  and Joint Broker) 
  Ben Maddison, Stewart Wallace                                         +44 (0)20 7710 7600 
 
 Allenby Capital Limited (Joint Broker)                                 +44 (0)20 3328 5656 
 James Reeve/George Payne (Corporate 
  Finance) 
 Stefano Aquilino (Sales & Corporate 
  Broking) 
 
 Walbrook PR (Media & Investor Relations)    +44 (0)20 7933 8780 or reneuron@walbrookpr.com 
                                                          +44 (0)7980 541 893 / +44 (0)7407 
 Paul McManus/Alice Woodings                                                        804 654

About ReNeuron

ReNeuron is a UK based Proprietary Stem Cell based Exosome Technologies company, harnessing its unique stem cell technologies to develop 'off the shelf' treatments for diseases with significant unmet needs.

ReNeuron's stem cell derived proprietary Exosome Technology platform offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. The Company has a growing number of partner collaborations with Global Pharma, Biotech and academic partners in this fast-expanding area of scientific and commercial interest. ReNeuron also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

The Company has out-licenced its CTX Programme for stroke disability and hRPC programme in retinitis pigmentosa to Fosun in China and is looking to out-licence both these programmes in other territories.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRBKOBDFBKDDNK

(END) Dow Jones Newswires

March 08, 2022 02:00 ET (07:00 GMT)

Reneuron (LSE:RENE)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025 Plus de graphiques de la Bourse Reneuron
Reneuron (LSE:RENE)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025 Plus de graphiques de la Bourse Reneuron